Delaying noncardiac surgeries for three to six months following a heart attack appears safer for those who undergo ...
Bayer will present three new prespecified subgroup analyses from the pivotal Phase III FINEARTS-HF cardiovascular outcomes trial investigating KERENDI ...
The flow cytometry-based assay measures the expression of the protein FcyR11a as a biomarker for cardiovascular risk.
OMRON Healthcare has received de novo authorization from the U.S. Food and Drug Administration (FDA) to market new home blood pressure monitors featuring AI-powered atrial fibrillation ...
AFib is the most common type of heart arrythmia 2. Left untreated, it increases risk of stroke, heart failure, myocardial ...
For patients with ischemic stroke, sodium-glucose cotransporter-2 inhibitors (SGLT-2is) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are associated with reduced mortality, myocardial ...
The study highlights BMI's role in mediating genetic risk for diseases, suggesting a complex relationship with conditions ...
People with chronic kidney disease, type 2 diabetes, or both of these conditions may have a higher cardiovascular disease ...
BACKGROUND: Many studies have explored whether individual plasma protein biomarkers improve cardiovascular disease risk prediction. We sought to investigate the use of a plasma proteomics-based ...
The risks of thromboembolism—blood clots blocking blood flow to organs—following COVID-19 vaccination in patients with atrial ...
Ischemia occurs when the heart does not receive adequate blood supply to function properly. "Cardiomyopathy" is an umbrella ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback